Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Maxcyte, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Commercial Physical & Biological Research
Prev close 1.19 · gapped above the open, then crossed back over prior close. High/low 1.20 at 10:45 am ET, 1.18 at 12:15 pm ET.
Maxcyte, Inc. has 1 disclosed supplier and 4 disclosed customers. Each one is named in an SEC filing, either Maxcyte, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In January 2025, we acquired SeQure Dx, ("SeQure") a market leader for on-target and off-target editing assessment services for cell and gene therapies.”
FILING10-K0001104659-26-034557cik 0001287098
“Although Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.”
FILING10-K0001104659-26-034557cik 0001287098
“Although Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.”
FILING10-K0001104659-26-034557cik 0001287098
“Although Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.”
FILING10-K0001104659-26-034557cik 0001287098
“From leading commercial cell therapy drug and biologic developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology.”
FILING10-K0001104659-26-034557cik 0001287098
Watchlist prices, news filtered to it, and its next report on your desk.
MXCT (Maxcyte, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: DTIL −3.50%, in healthcare.